Comparative Pharmacology
Head-to-head clinical analysis: PROTONIX IV versus RABEPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTONIX IV versus RABEPRAZOLE SODIUM.
PROTONIX IV vs RABEPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Rabeprazole is a proton pump inhibitor (PPI) that inhibits the gastric H+/K+-ATPase enzyme at the secretory surface of gastric parietal cells, thereby suppressing basal and stimulated gastric acid secretion. It is a substituted benzimidazole that accumulates in the acidic environment of the parietal cell and is protonated, forming a covalent disulfide bond with cysteine residues of the proton pump, leading to irreversible inhibition.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
Oral: 20 mg once daily; duodenal ulcer: 20 mg once daily for up to 4 weeks; erosive esophagitis: 20 mg once daily for 4 to 8 weeks; GERD: 20 mg once daily for 4 to 8 weeks; Helicobacter pylori eradication: 20 mg twice daily in combination with antibiotics.
None Documented
None Documented
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
1-2 hours in most individuals, but pharmacodynamic half-life is longer (24-48 hours) due to irreversible binding to proton pumps; clearance is reduced in hepatic impairment (half-life up to 12 hours)
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Primarily renal (approx. 90% as metabolites, <1% unchanged) and fecal (approx. 10%)
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor